ES2172179T3 - Composiciones farmaceuticas de liberacion controlada que contienen tiagabina. - Google Patents

Composiciones farmaceuticas de liberacion controlada que contienen tiagabina.

Info

Publication number
ES2172179T3
ES2172179T3 ES98937738T ES98937738T ES2172179T3 ES 2172179 T3 ES2172179 T3 ES 2172179T3 ES 98937738 T ES98937738 T ES 98937738T ES 98937738 T ES98937738 T ES 98937738T ES 2172179 T3 ES2172179 T3 ES 2172179T3
Authority
ES
Spain
Prior art keywords
hours
controlled release
tiagabine
thiagabine
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98937738T
Other languages
English (en)
Inventor
Maurice Joseph Anthony Clancy
Michelle Caulfield
Kenneth Iain Cumming
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Co PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26320083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2172179(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IE19970588A external-priority patent/IE970588A1/en
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Application granted granted Critical
Publication of ES2172179T3 publication Critical patent/ES2172179T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un preparado farmacéutico oral de liberación controlada que comprende una cantidad terapéuticamente eficaz de tiagabinetiagabina o una de sus sales farmacéuticamente aceptable dispersada en una matriz polimérica que controlacontroladora de la velocidad que comprende al menos un polímero que controlacontrolador de la velocidad, cuyo preparado que proporciona niveles, terapéuticamente eficaces, de tiagabinetiagabina en plasma durante un período de al menos 12 horas, y que proporciona un perfil medio de disolución in vitro, en medios acuosos, tal que aproximadamente 5 a 40% de tiagabinetiagabina se libera después de 1 hora; aproximadamente 25 a 65% de tiagabinetiagabina se libera después de 4 horas; aproximadamente 55 a 95% de tiagabinetiagabina se libera después de 10 horas y aproximadamente 80 a 100% de tiagabinetiagabina se libera después de 22 horas, cuando se lleva a cabo en un Aparato USP (II) ()de paletas) a50 r.p.m. en agua desionizada a 37ºC como medio para la disolución.
ES98937738T 1997-08-01 1998-07-30 Composiciones farmaceuticas de liberacion controlada que contienen tiagabina. Expired - Lifetime ES2172179T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5443297P 1997-08-01 1997-08-01
IE19970588A IE970588A1 (en) 1997-08-01 1997-08-08 Controlled release pharmaceutical compositions containing tiagabine

Publications (1)

Publication Number Publication Date
ES2172179T3 true ES2172179T3 (es) 2002-09-16

Family

ID=26320083

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98937738T Expired - Lifetime ES2172179T3 (es) 1997-08-01 1998-07-30 Composiciones farmaceuticas de liberacion controlada que contienen tiagabina.

Country Status (10)

Country Link
EP (1) EP0991409B1 (es)
JP (1) JP2001511450A (es)
AT (1) ATE212550T1 (es)
AU (1) AU8643698A (es)
CA (1) CA2299464C (es)
DE (1) DE69803670T2 (es)
DK (1) DK0991409T3 (es)
ES (1) ES2172179T3 (es)
PT (1) PT991409E (es)
WO (1) WO1999006045A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002325404B2 (en) * 1998-01-22 2006-02-02 Abbott Laboratories Extended Release Tiagabine Formulations with Reduced Side-effects
ZA99407B (en) * 1998-01-22 1999-07-20 Abbott Lab Extended release tiagabine formulations with reduced side-effects.
RU2220715C2 (ru) * 1999-08-04 2004-01-10 Яманоути Фармасьютикал Ко., Лтд. Стабильная пероральная, образующая гидрогель, фармацевтическая композиция, способ ее получения, способ предотвращения изменений высвобождения лекарственного средства, способ увеличения физической стабильности пероральной композиции
KR100510270B1 (ko) * 2002-11-29 2005-08-26 센츄론(주) 펠렛타이저를 이용한 서방성 제제의 제조방법
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
WO2004082615A2 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5750140A (en) * 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
MX9708394A (es) * 1995-05-05 1998-02-28 Novo Nordisk As Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
EP0912091B1 (en) * 1996-05-24 2007-12-19 Smithkline Beecham Corporation Use of gaba uptake inhibitors as anti-tussive agents
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders

Also Published As

Publication number Publication date
EP0991409A1 (en) 2000-04-12
EP0991409B1 (en) 2002-01-30
DK0991409T3 (da) 2002-03-25
CA2299464C (en) 2009-02-17
WO1999006045A1 (en) 1999-02-11
DE69803670D1 (de) 2002-03-14
AU8643698A (en) 1999-02-22
DE69803670T2 (de) 2002-11-21
JP2001511450A (ja) 2001-08-14
PT991409E (pt) 2002-06-28
CA2299464A1 (en) 1999-02-11
ATE212550T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
DK0688214T3 (da) Fremgangsmåder til inhibering af knogletab med 3,4-diarylchroman
MY115662A (en) Novel compounds with analgesic effect
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
TR200100931T2 (tr) Yeni sürekli salınımlı oral formülasyonlar
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
NO971206D0 (no) Forlenget-frigjöringsformulering
GEP20032925B (en) Benzothiepines Having Activity As Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake
IL121126A0 (en) Method of increasing expression of molecular chaperon by an eukarytic cell
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
ATE305473T1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
PT1051159E (pt) Composicoes farmaceuticas solidas contendo miltefosina para administracao oral no tratamento de leishmaniose
ES2172179T3 (es) Composiciones farmaceuticas de liberacion controlada que contienen tiagabina.
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
FI933975A0 (fi) Tabletter som kontrollerat avgiver naproxen
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
BR0014440A (pt) Formulações de liberação controlada oral
BRPI0415546A (pt) composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios
ATE194498T1 (de) Wasserfreies mittel auf lactulosebasis
SE0002354D0 (sv) New formulation
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
ES2165734T3 (es) Composiciones basadas en pentoxifilina y anticitoquina.
PT986390E (pt) Composicoes farmaceuticas que contem cicloridrato de cinchonina
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 991409

Country of ref document: ES